Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|August 1, 2019
Fujifilm Extends Regional Presence Through Danish Acquisition
Author(s)Pharmaceutical Technology Editors
Fujifilm has bought Biogen ApS’ Copenhagen facility for US$890 million.
Advertisement
Fujifilm Diosynth Biotechnologies has acquired Biogen Manufacturing ApS near Copenhagen, Denmark for US$890 million in cash, according to a company press release that was issued on Aug. 1, 2019. This is the fourth facility that the contract development and manufacturing organization (CDMO) has acquired since it was established in 2011.
The new site has nearly 800 employees and includes a large-scale production facility with six 15,000-L bioreactors; an assembly, labeling and packaging facility; and quality control laboratories and warehouses.
“We will seek to continue the further advancement of the pharmaceutical industry by serving our range of diverse customers’ needs through combining resources of the Biogen (Denmark) Manufacturing ApS and Fujifilm,” said Takatoshi Ishikawa, executive vice president and general manager of Fujifilm Corporation’s Bio CDMO division, in the press release.
Source:
Advertisement
Related to this article
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, explains the demand for spray drying and the hurdles involved with scale up, in an interview with PharmTech.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
What the Olanzapine Depot Approval Means for CMC Teams
3
PharmTech AI Pulse Check: Availability Bias Threatens AI Regulatory Reviews
4
Complying with International Pharmacopoeias
5